sprite-preloader
Anzeige
Mehr »
Sonntag, 21.10.2018 Börsentäglich über 12.000 News von 596 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
SaESMO: Roche's Tecentriq posts 'unprecedented' benefit in triple-negative breast cancer
SaESMO: Pfizer's narrow Ibrance survival miss could still sway docs in its favor: exec
FrAbbVie CFO Chase spearheaded its Abbott spinoff and Imbruvica buy-and now he's retiring
FrNICE spurns Lilly's breast cancer drug Verzenio in favor of rivals from Pfizer and Novartis
FrPanel backing for key Shire drug beefs up Takeda's case for its $62B buyout
FrAfter Philippines safety scandal, Sanofi's Dengvaxia set for European approval
FrFiercePharmaAsia-China's $1.3B vaccine fine; Lantus biosim retreat; Taiho's VC fund
FrESMO 2018 spotlights Merck's Keytruda, Pfizer's Ibrance, AstraZeneca's Lynparza and more
FrClovis bolsters Rubraca's PARP-leading prostate cancer bid with big-time response data
DoNovartis' canakinumab gets an FDA rejection, but it raises guidance anyway
DoMerck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win
DoInsys drove 'explosive' opioid painkiller sales by 'owning' physicians, Senate report reveals
DoAbbVie wards off another Humira biosim challenger with Fresenius Kabi settlement
DoGlaxoSmithKline's job whacking touches U.S. consumer plant
DoWorking through CEO swap, Pfizer plots job cuts in drive for 'simpler' structure
MiEven in worst-case scenario, Roche will grow past biosimilar erosion in the U.S.: executive
MiMannkind's Afrezza Facebook page gets slapped by FDA's promo police
MiU.K. fights EpiPen shortage by extending injector expiry dates
MiMinnesota AG targets Sanofi, Eli Lilly and Novo Nordisk in latest insulin pricing attack
MiCan Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?
MiAmgen, Lilly migraine drugs nab Express Scripts backing, but Teva's shut out
MiMerck joins Novartis, GSK in grabbing a consumer exec to beef up digital
MiFDA spanks South Korea's Hanlim Pharm with warning letter
MiOfficials deny shortage of Seqirus' Fluad in the U.K. as season nears
MiNews of Note-Sanofi's Dengvaxia, HPV vaccine and more